证券日报网讯 10月21日晚间，国药股份发布2025年第三季度报告称，2025年第三季度公司实现营业收 入13，747，350，727.81元，同比增长3.58%；归属于上市公司股东的净利润为543，717，921.74元， 同比增长13.10%。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) has reported its subsidiary China National Pharmaceutical Co., Ltd. (国药股份) financial performance for the first three quarters of 2025, showing modest growth in revenue and net profit [1] Group 2 - The company achieved a revenue of 39.381 billion yuan, representing a year-on-year increase of 3.56% [1] - The net profit attributable to shareholders of the listed company was 1.492 billion yuan, reflecting a year-on-year growth of 0.74% [1] - The non-recurring net profit was 1.47 billion yuan, which indicates a year-on-year decline of 1.27% [1] - The basic earnings per share stood at 1.9778 yuan [1]

智通财经APP讯，国药控股(01099)公布附属国药股份(600511.SH)2025年前三季度业绩，公司前三季度 实现营收393.81亿元，同比增长3.56%;归属于上市公司股东的净利润14.92亿元，同比增长0.74%;扣非净 利润14.7亿元，同比下降1.27%;基本每股收益1.9778元。 ...

每经AI快讯，国药股份10月21日晚间发布公告称，公司第八届第三十一次董事会会议于2025年10月21 日以现场结合通讯表决方式召开。会议审议了《国药股份2025年第三季度报告》等文件。 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 （记者 曾健辉） ...

证券代码：600511 证券简称：国药股份 公告编号：临 2025-036 国药集团药业股份有限公司 第八届董事会第三十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、 董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第三十一次会议通知及资料于 2025 年 10 月 10 日以书面、电子邮件等形式发出，会议于 2025 年 10 月 21 日 以现场结合通讯表决方式召开。本次会议应到董事九名，实到董 事九名，其中四名独立董事参加了会议，董事长刘月涛先生主持 本次会议，部分高管列席会议，符合《公司法》和《公司章程》 的有关规定。 特此公告。 国药集团药业股份有限公司董事会 2025 年 10 月 22 日 2 二、 董事会会议审议情况 本次会议审议并通过了如下决议： （一）以 9 票同意、0 票反对和 0 票弃权的结果审议通过《国 药股份 2025 年第三季度报告》。 在提交本次董事会之前，该议案已经董事会审计委员会审议， 1 全体委员一致同意提交董事会审议。 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥13,747,350,727.81, representing a year-on-year increase of 3.58%[4] - The total profit for the period was ¥707,162,533.10, reflecting a year-on-year growth of 9.13%[4] - The net profit attributable to shareholders was ¥543,717,921.74, which is a 13.10% increase compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.7206, up by 13.10% year-on-year[5] - Total operating revenue for the first three quarters of 2025 reached ¥39.38 billion, an increase of 3.56% compared to ¥38.03 billion in the same period of 2024[20] - Net profit for the first three quarters of 2025 was ¥1.56 billion, slightly down from ¥1.57 billion in 2024, representing a decrease of 0.66%[21] - Earnings per share for the first three quarters of 2025 were ¥1.9778, compared to ¥1.9632 in the same period of 2024, indicating a growth of 0.75%[22] - The net profit for the first three quarters of 2025 was ¥1,260,310,854.59, representing a growth of 8.2% from ¥1,164,577,361.68 in the first three quarters of 2024[31] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥35,125,161,234.99, showing a slight increase of 0.56% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to ¥25.03 billion, a decrease from ¥26.82 billion at the end of 2024[27] - The company's current assets totaled RMB 30,528,913,480.03, slightly up from RMB 30,356,823,125.08 in the previous period[15] - The total liabilities decreased to RMB 20,000,000,000 from RMB 21,000,000,000, indicating a reduction of about 4.8%[15] - The company's total liabilities decreased to ¥15.19 billion in 2025 from ¥15.95 billion in 2024, a reduction of 4.77%[18] - The total liabilities decreased from ¥12,992,254,186.56 to ¥10,517,805,019.29, indicating a reduction of approximately 18.6%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,584[10] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 54.72% of the shares, amounting to 412,841,745 shares[10] Cash Flow - The company reported a net cash flow from operating activities of ¥-2,050,432,782.11 for the year-to-date[4] - Cash inflow from operating activities for the first three quarters of 2025 reached ¥40.19 billion, compared to ¥39.56 billion in the same period of 2024, reflecting an increase of approximately 1.8%[24] - Net cash outflow from operating activities was ¥2.05 billion in 2025, worsening from a net outflow of ¥1.03 billion in 2024[25] - The cash flow from operating activities for the first three quarters of 2025 was ¥66,823,988.11, a decline of 82.1% compared to ¥372,998,879.56 in the same period of 2024[34] Investment and Expenses - Investment income for the first three quarters of 2025 was ¥440.99 million, an increase of 39.3% from ¥316.41 million in 2024[21] - Research and development expenses for the first three quarters of 2025 were ¥43.59 million, slightly down from ¥44.14 million in 2024, a decrease of 1.25%[20] - The company reported a financial expense of -¥16.58 million in 2025, a significant improvement compared to -¥73.67 million in 2024[20] - The financial expenses showed a significant improvement, with a net financial income of ¥5,952,984.57 in 2025 compared to a loss of ¥54,920,861.91 in 2024[30] Other Comprehensive Income - Non-recurring gains and losses for the period totaled ¥5,074,780.26, with significant contributions from government subsidies and asset disposals[8] - Other comprehensive income after tax for the first three quarters of 2025 was ¥25,861,163.15, compared to a loss of -¥4,446,206.50 in the same period of 2024[31]

Core Insights - The company reported a net profit increase of 13.10% year-on-year for the third quarter of 2025 [1] - The total revenue for the third quarter reached 13.747 billion yuan, reflecting a year-on-year growth of 3.58% [1] Financial Performance - The company's revenue for Q3 2025 was 13.747 billion yuan, which is an increase of 3.58% compared to the same period last year [1] - The net profit attributable to shareholders was 544 million yuan, showing a growth of 13.10% year-on-year [1]

Core Insights - The company reported third-quarter revenue of 13.747 billion, representing a year-on-year increase of 3.58% [1] - Net profit for the third quarter was 544 million, showing a year-on-year growth of 13.10% [1] - For the first three quarters, total revenue reached 39.381 billion, with a year-on-year growth of 3.56% [1] - Net profit for the first three quarters was 1.492 billion, reflecting a year-on-year increase of 0.74% [1]

Core Viewpoint - China National Pharmaceutical Group Corporation (国药股份) reported a revenue of 39.381 billion yuan for the first three quarters, reflecting a year-on-year growth of 3.56% [1] - The net profit attributable to shareholders reached 1.492 billion yuan, showing a slight increase of 0.74% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 1.47 billion yuan, indicating a year-on-year decline of 1.27% [1] - Basic earnings per share stood at 1.9778 yuan [1] Financial Performance - Revenue for the first three quarters: 39.381 billion yuan, up 3.56% year-on-year [1] - Net profit attributable to shareholders: 1.492 billion yuan, up 0.74% year-on-year [1] - Net profit after deducting non-recurring items: 1.47 billion yuan, down 1.27% year-on-year [1] - Basic earnings per share: 1.9778 yuan [1]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]